Extended Data Fig. 5: Medications are not a major contributor to the PD-associated DNA methylation changes identified in this study.
From: Epigenomic analysis of Parkinson’s disease neurons identifies Tet2 loss as neuroprotective
a, Heatmap correlations and unsupervised clustering of patient covariates (yellow: positively correlated, blue: negatively correlated; Pearson’s correlation). b, Venn diagram showing the overlap of differentially methylated cytosines at enhancers in PD patients (n = 57 PD, 48 controls) with differentially methylated cytosines related to PD patients taking dopamine agonists, COMT inhibitors, and/or MAO-B inhibitors. Differentially methylated cytosines related to PD medications were identified by logistic regression, after adjusting for age, sex, postmortem interval, and neuronal subtypes (q < 0.05, multiple testing corrected). c, Intersection of genes with differential methylation in PD and with differential methylation in response to levodopa (L-Dopa) in the brain of a rat model of PD (dorsal striatum of 6-OHDA–treated rats receiving L-Dopa)9,29. Enrichment determined by Fisher’s exact test.
